Breast implant rupture occurs when the outer shell of a breast implant develops a tear or hole, allowing the contents to leak. Both silicone gel and saline implants can rupture, and the consequences differ significantly depending on implant type. MRI is the most accurate test for detecting silicone implant rupture — particularly the silent intracapsular variety — and is the FDA-recommended screening tool for all women with silicone implants.
Breast implant rupture is a unique condition in this section — it is the only Women's Health condition evaluated primarily with breast rather than pelvic MRI. Approximately 400,000 breast augmentation procedures are performed annually in the United States, making implant surveillance a significant and growing clinical need. Because silicone ruptures are frequently asymptomatic and can go undetected for years, MRI screening is not just diagnostically useful — it is a proactive health measure that the FDA formally recommends on a scheduled basis, regardless of symptoms.
Causes
Age of the implant.
All breast implants have a finite lifespan — they are not lifetime devices. The probability of rupture increases steadily and predictably with implant age. Studies suggest cumulative rupture rates of approximately 1% per year, meaning that by 10 years roughly 10% of implants have ruptured, and by 20 years the majority may have some degree of shell failure. This is particularly relevant for older-generation implants placed in the 1980s and 1990s, which had thinner shells and higher rupture rates than current cohesive gel devices. Women with implants of any age should be aware that eventual shell failure is an expected biological reality rather than a sign of surgical complication.
Other causes.
Acute ruptures can result from direct chest trauma — motor vehicle accidents, severe blunt force, or falls — sufficient to compress and shear the implant shell. Iatrogenic rupture during core needle biopsy, fine needle aspiration, or surgical procedures near the implant is a recognized risk. Capsular contracture — the abnormal tightening of the fibrous scar tissue capsule that forms around every implant — exerts chronic compressive and shear forces on the shell and is a significant predictor of eventual rupture. Fold flaw failure, in which the shell repeatedly folds and unfolds at the same point under normal animation, causes metal-fatigue-like micro-tears that propagate over time. Manufacturing defects in older implant generations contributed to historically higher rupture rates.
Symptoms
The symptom profile differs dramatically between implant types. Saline implant ruptures are clinically unmistakable — the saline leaks rapidly into surrounding tissue where it is harmlessly absorbed, and the breast visibly deflates and loses volume over hours to days, with an obvious change in size, shape, and projection. No imaging is required for diagnosis.
Silicone implant ruptures are frequently "silent" — the cohesive gel in modern implants is designed to remain within the fibrous capsule even when the shell is torn, producing no immediate change in breast appearance or feel. A woman may carry an intracapsular rupture for months or years without any awareness. When symptoms do occur they may include a subtle change in breast shape or contour, development of new firmness or lumps, breast pain or tenderness, tingling, or numbness — all of which can also be caused by capsular contracture or other benign conditions, making clinical diagnosis unreliable. Extracapsular rupture — when silicone has escaped beyond the capsule — may produce more noticeable lumps in the breast or axilla from silicone granuloma formation, and occasionally axillary lymph node involvement.
Diagnosis
Saline implant rupture requires no imaging — clinical diagnosis is immediate and obvious. Silicone implant rupture, by contrast, requires dedicated imaging for reliable detection.
Breast MRI is the gold standard for silicone implant evaluation, with sensitivity and specificity well above 90% for rupture detection — far exceeding mammography (which cannot visualize the implant interior) and ultrasound (which is adequate for extracapsular rupture but poorly sensitive for intracapsular rupture). The characteristic MRI finding of intracapsular rupture is the "linguine sign" — multiple curvilinear low-signal lines floating within the silicone, representing the collapsed and folded implant shell suspended within the intact outer capsule. Extracapsular rupture is identified by silicone signal extending through the fibrous capsule into the adjacent breast parenchyma or axillary soft tissues. The "teardrop sign" and "droplet sign" describe specific patterns of extracapsular silicone migration. MRI also evaluates the surrounding breast tissue for silicone granulomas, lymphadenopathy, and any suspicious breast lesions — providing a comprehensive breast health assessment alongside the implant evaluation.
The FDA recommends MRI screening for silicone gel-filled breast implants beginning 5–6 years after placement and every 2–3 years thereafter, even in the complete absence of symptoms, because the high rate of clinically silent intracapsular ruptures makes symptom-based detection unreliable. Ultrasound is an accessible alternative for patients who cannot undergo MRI, but should be interpreted with the understanding that its sensitivity for intracapsular rupture is substantially lower.
Classification
Silicone implant rupture is classified by the anatomic location of the escaped silicone relative to the fibrous capsule.
- Intracapsular rupture: The silicone gel remains contained within the fibrous capsule despite a torn implant shell. The most common type. Diagnosed by the linguine sign on MRI. Typically asymptomatic — discovered only on screening imaging. The outer capsule continues to contain the gel, but the protective implant shell is no longer intact.
- Extracapsular rupture: Silicone has escaped through both the implant shell and the surrounding fibrous capsule into adjacent breast tissue or the axilla. Less common but clinically more significant — silicone granulomas may form and axillary lymph nodes may become involved. Identified on MRI by silicone signal external to the capsule.
- Gel bleed: Microscopic diffusion of silicone through an intact, unruptured shell into the surrounding tissue — a normal phenomenon with older generation implants and not classified as true rupture. Modern highly cohesive gel devices have substantially reduced gel bleed.
Treatments
Treatment depends on implant type, rupture classification, symptom burden, and patient preference.
Saline rupture: The leaked saline is harmlessly absorbed by the body, posing no health risk. However, the deflated shell remains and should be removed. Surgical explantation is a straightforward outpatient procedure; replacement with a new implant at the same time is the most common approach, though some patients choose not to replace.
Silicone implant rupture.
Current FDA guidance recommends explantation of ruptured silicone implants even when asymptomatic, though the decision is ultimately individualized based on symptoms, patient preference, and surgical risk. Surgery involves explantation of the implant combined with en bloc total capsulectomy — removal of the implant and its surrounding fibrous capsule as a single unit — to maximize removal of any contained silicone and minimize residual silicone burden in the breast. For extracapsular ruptures, identification and removal of silicone granulomas and affected lymph nodes may be required. Patients may choose simultaneous replacement with new implants, reconstruction with fat grafting, or to remain without implants. The choice of capsulectomy technique — total vs. partial — and the surgical approach should be discussed with a board-certified plastic surgeon experienced in revision breast surgery.
Breast implant illness (BII) considerations.
Some women with breast implants report a constellation of systemic symptoms including fatigue, cognitive difficulty, joint pain, and rash — collectively termed breast implant illness — that they attribute to their implants. The relationship between implants and these symptoms remains under active investigation. Some patients report significant improvement after explantation. Women experiencing unexplained systemic symptoms alongside breast implants should discuss the possibility of explantation with their surgeon.
Screening recommendations.
The FDA recommends MRI screening beginning 5–6 years after silicone implant placement and every 2–3 years thereafter, regardless of symptoms. Women who had implants placed before this recommendation was widely communicated — particularly those with implants over 10 years old — should discuss their screening status with their plastic surgeon or primary care provider. Given that MRI is not covered by most insurance for asymptomatic screening, First Look MRI provides affordable, accessible screening MRI for implant surveillance without a referral.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Pelvis MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.